Roslin Cells granted MIA (IMP) licence

Fantastic news from Scotland where Rosilin Cells Ltd. have announced they have been granted by the Medicines and Health Regulatory Authority (MHRA) a Manufacturer's Authorisation for Investigational Medicinal Products, MIA(IMP), for their GMP cellular therapy facility. In addition they have been awarded a 'Specials' licence that covers manufacture of ATMPs for specific patients. 

The company operates a seven clean room GMP manufacture facility tin partnership with the Scottish National Blood Transfusion Service (SNBTS) within the Scottish Centre for Regenerative Medicine (SCRM). Roslin Cells are focused on the development and manufacture of human embryonic stem cell (hESC) and induced pluripotent stem cell (iPS) lines, and have a collaboration with ACT.
Importantly this facility will now be available to companies and academic researchers under this licence

Roslin Cells press release